First Eagle Investment Management’s TherapeuticsMD TXMD Stock Holding History

First Eagle Investment Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-26,486	Closed	-$1.4M	–	108
2020 Q1	$1.4M	Hold	26,486	–	–	0.01%	108
2019 Q4	$3.21M	Sell	26,486 -2,391	-8%	-$344K	0.01%	101
2019 Q3	$5.24M	Hold	28,877	–	–	0.01%	99
2019 Q2	$3.75M	Hold	28,877	–	–	0.01%	122
2019 Q1	$7.03M	Sell	28,877 -8,591	-23%	-$2.27M	0.02%	119
2018 Q4	$7.14M	Sell	37,468 -19,823	-35%	-$4.84M	0.02%	120
2018 Q3	$18.8M	Buy	57,291 +12,136	+27%	+$3.72M	0.05%	115
2018 Q2	$14.1M	Buy	45,155 +10,208	+29%	+$3.12M	0.03%	122
2018 Q1	$8.51M	Buy	34,947 +3,585	+11%	+$1.01M	0.02%	129
2017 Q4	$9.47M	Buy	+31,362	New	+$8.73M	0.02%	150

Other funds holding TXMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Eagle Investment Management's TXMD Position: Q2 2020 in Review

First Eagle Investment Management sold out of TherapeuticsMD (TXMD) in Q2 2020, closing a stake of 26,486 shares — an estimated $1.4M sold.

First Eagle Investment Management first reported a position in TXMD in Q4 2017 and held it in 10 quarters. The position peaked at $18.8M in Q3 2018. 149 funds tracked by Wall St. Rank hold TXMD as of Q2 2020.

First Eagle Investment Management reported no remaining TherapeuticsMD position as of Q2 2020 after selling out during the quarter.
First Eagle Investment Management sold 26,486 TherapeuticsMD shares in Q2 2020, an estimated $1.4M.
First Eagle Investment Management first reported a position in TherapeuticsMD in Q4 2017 and held it in 10 quarters.
First Eagle Investment Management's TherapeuticsMD position peaked at $18.8M in Q3 2018.
149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2020.

Based on First Eagle Investment Management's 13F filing for Q2 2020, filed 10 Aug 2020.